All News

    FDA Grants Breakthrough Therapy to IDE196 in Primary Uveal Melanoma

    April 4th 2025, 4:06pm

    Article

    The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when enucleation has been recommended.

    FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer

    April 4th 2025, 3:12pm

    Article

    The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type of brain cancer.

    Machine Learning Improves Transplant Risk Assessment in Myelofibrosis

    April 4th 2025, 1:00pm

    Video

    Machine learning model improves transplant risk assessment for patients with myelofibrosis, helping clinicians make informed decisions, as per an expert.

    Survey Findings Reveal Financial Challenges in Patients with Cancer

    April 3rd 2025, 9:00pm

    Article

    Among patients with cancer, high out-of-pocket costs were found to impact access to health care, adherence to medication, as well as quality of life.

    Breaking Down Kidney Cancer Treatment Advancements and Providing Hope

    April 3rd 2025, 8:00pm

    Video

    Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.

    Breaking Down Early Signs and Symptoms of Head and Neck Cancer

    April 3rd 2025, 7:00pm

    Article

    April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.

    How Breast Cancer Taught Me Resilience in Unexpected Life Challenges

    April 3rd 2025, 5:00pm

    Article

    Lessons I learned from a cancer diagnosis have been applied in some surprising and seemingly unrelated aspects of my life.

    NG-350A Evaluated in FORTRESS Trial for Locally Advanced Rectal Cancer

    April 3rd 2025, 4:01pm

    Article

    The first patient with locally advanced rectal cancer has been enrolled in the FORTRESS study which is evaluating the investigative immunotherapy NG-350A.

    Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial

    April 3rd 2025, 3:00pm

    Article

    Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for further treatment expansion.

    Development of Nemvaleukin for Platinum-Resistant Ovarian Cancer Halted

    April 3rd 2025, 1:00pm

    Article

    A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on to final analysis.